Literature DB >> 28118686

Two-sample binary phase 2 trials with low type I error and low sample size.

Samuel Litwin1, Stanley Basickes2, Eric A Ross1.   

Abstract

We address design of two-stage clinical trials comparing experimental and control patients. Our end point is success or failure, however measured, with null hypothesis that the chance of success in both arms is p0 and alternative that it is p0 among controls and p1  > p0 among experimental patients. Standard rules will have the null hypothesis rejected when the number of successes in the (E)xperimental arm, E, sufficiently exceeds C, that among (C)ontrols. Here, we combine one-sample rejection decision rules, E⩾m, with two-sample rules of the form E - C > r to achieve two-sample tests with low sample number and low type I error. We find designs with sample numbers not far from the minimum possible using standard two-sample rules, but with type I error of 5% rather than 15% or 20% associated with them, and of equal power. This level of type I error is achieved locally, near the stated null, and increases to 15% or 20% when the null is significantly higher than specified. We increase the attractiveness of these designs to patients by using 2:1 randomization. Examples of the application of this new design covering both high and low success rates under the null hypothesis are provided.
Copyright © 2017 John Wiley & Sons, Ltd. Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  binary comparisons; low sample number; low type I error; phase II clinical trials; two-stage

Mesh:

Year:  2017        PMID: 28118686      PMCID: PMC5378610          DOI: 10.1002/sim.7226

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  3 in total

1.  Randomized phase II trials with a prospective control.

Authors:  Sin-Ho Jung
Journal:  Stat Med       Date:  2008-02-20       Impact factor: 2.373

2.  Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group.

Authors:  Julie Francart; Catherine Legrand; Richard Sylvester; Martine Van Glabbeke; Jan P van Meerbeeck; Annie Robert
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

3.  Optimal two-stage designs for phase II clinical trials.

Authors:  R Simon
Journal:  Control Clin Trials       Date:  1989-03
  3 in total
  4 in total

1.  A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1).

Authors:  Marijo Bilusic; Nicole J Toney; Renee N Donahue; Susan Wroblewski; Matthew Zibelman; Pooja Ghatalia; Eric A Ross; Fatima Karzai; Ravi A Madan; William L Dahut; James L Gulley; Jeffrey Schlom; Elizabeth R Plimack; Daniel M Geynisman
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-01-25       Impact factor: 5.455

2.  A stochastically curtailed two-arm randomised phase II trial design for binary outcomes.

Authors:  Martin Law; Michael J Grayling; Adrian P Mander
Journal:  Pharm Stat       Date:  2020-08-29       Impact factor: 1.894

3.  Practical and robust test for comparing binomial proportions in the randomized phase II setting.

Authors:  Kristopher Attwood; Soyun Park; Alan D Hutson
Journal:  Pharm Stat       Date:  2021-10-09       Impact factor: 1.234

4.  Correlation Coefficients for a Study with Repeated Measures.

Authors:  Guogen Shan; Hua Zhang; Tao Jiang
Journal:  Comput Math Methods Med       Date:  2020-03-26       Impact factor: 2.238

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.